Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.59 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.59 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.59 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.59 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.59 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.58 |
| ▸ | PKM | P14618 | 3/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.54 |
| ▸ | CA12 | O43570 | 2/20 | 0.51 |
| ▸ | CA1 | P00915 | 2/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.51 |
| ▸ | CA9 | Q16790 | 2/20 | 0.51 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ABL1 | P00519 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | IDE | P14735 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12102937 | 1.00 | F2 (0.59) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL2608510 | 1.00 | F2 (0.59) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL24637661 | 0.99 | F2 (0.60) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL12937922 | 0.99 | F2 (0.60) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL31510307 | 0.99 | F2 (0.60) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL23077610 | 0.99 | F2 (0.60) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL10191035 | 0.99 | F2 (0.60) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL15315671 | 0.99 | F2 (0.60) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL19543682 | 0.99 | F2 (0.60) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL31661152 | 0.99 | F2 (0.60) | F2PRSS1PRSS2PRSS3TPSAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3658171-B1 | MULTI-EPITOPE FUSION PROTEIN OF AN HCV ANTIGEN AND USES THEREOF | ROCHE DIAGNOSTICS GMBH (DE) | 2023-08-30 | — | — | EP | disclosed |
| US-20220317119-A1 | PARTICLE-BASED IMMUNOASSAY USING A PEGYLATED ANALYTE-SPECIFIC BINDING AGENT | ROCHE DIAGNOSTICS GMBH (DE) | 2022-10-06 | — | — | US | disclosed |
| US-11078241-B2 | Multi-epitope fusion protein of an HCV antigen and uses thereof | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-20200148726-A1 | MULTI-EPITOPE FUSION PROTEIN OF AN HCV ANTIGEN AND USES THEREOF | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2020-05-14 | — | — | US | disclosed |
| US-20190346432-A1 | IMMUNOASSAY USING AT LEAST TWO PEGYLATED ANALYTE-SPECIFIC BINDING AGENTS | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2019-11-14 | — | — | US | disclosed |
| US-20180172680-A1 | PARTICLE-BASED IMMUNOASSAY USING A PEGYLATED ANALYTE-SPECIFIC BINDING AGENT | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2018-06-21 | — | — | US | disclosed |
| US-20180172680-A1 | PARTICLE-BASED IMMUNOASSAY USING A PEGYLATED ANALYTE-SPECIFIC BINDING AGENT | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2018-06-21 | — | — | US | disclosed |
| US-9675589-B2 | Methods of inhibiting cataracts and presbyopia | UNIVERSITY OF MASSACHUSETTS (US) | 2017-06-13 | — | — | US | disclosed |
| US-20170107248-A1 | SITE SPECIFIC PROTEIN MODIFICATIONS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2017-04-20 | — | — | US | disclosed |
| US-20160074370-A1 | METHODS OF INHIBITING CATARACTS AND PRESBYOPIA | UNIVERSITY OF MASSACHUSETTS | 2016-03-17 | — | — | US | disclosed |
| WO-2015200080-A1 | SITE SPECIFIC PROTEIN MODIFICATIONS | NOVARTIS AG (CH) | 2015-12-30 | — | — | WO | disclosed |
| US-7560284-B2 | Fine particles containing rare earth element and fluorescent probe using the same | DAI NIPPON PRINTING CO., LTD. (JP) | 2009-07-14 | — | — | US | disclosed |
| US-20080292520-A1 | FINE PARTICLES CONTAINING RARE EARTH ELEMENT AND FLUORESCENT PROBE USING THE SAME | MATSUURA DAISUKE | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11078241-B2 | Multi-epitope fusion protein of an HCV antigen and uses thereof | MICA, HAVCR2, HSP90B1 | F2 3647/4885PRSS1 2362/4885PRSS2 2165/4885 |
| US-20170107248-A1 | SITE SPECIFIC PROTEIN MODIFICATIONS | PTMS, DNPEP, ANPEP | F2 2801/4885PRSS1 768/4885PRSS2 779/4885 |
| US-20160074370-A1 | METHODS OF INHIBITING CATARACTS AND PRESBYOPIA | CRYAB, CRYAA, CRYZ | F2 3369/4885PRSS1 2064/4885PRSS2 2065/4885 |
| US-20200148726-A1 | MULTI-EPITOPE FUSION PROTEIN OF AN HCV ANTIGEN AND USES THEREOF | MICA, HAVCR2, HSP90B1 | F2 3647/4885PRSS1 2362/4885PRSS2 2165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.